

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 01	Basic & Experimental 1	10296	Jui-Chi Yu	Poly(ethylene Glycol)-Block-Poly(cysteine) Block Copolymer-Based Self-Assembling Nanoparticles Attenuate Oxidative Stress in Primary Human Hepatocytes	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 01	Basic & Experimental 1	10324	Li-Wen Lin	Soat-Mediated Cholesterol Esterification Safeguards Against Hepatocyte Senescence and Inflammatory Sasp Activation	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 01	Basic & Experimental 1	10271	Koji Fujita	Investigation of Metabolic Pathways Associated with Sensitivity to Multikinase Inhibitors in Hepatocellular Carcinoma	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 01	Basic & Experimental 1	10146	Firman Alamsyah	The Effect of Electro-Capacitive Cancer Therapy on Liver Tumor Growth in Mice	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 01	Basic & Experimental 1	10353	Wan-Chieh Li	Cross-Platform Transcriptomic Mapping for Conserved Molecular Axes of Disease Progression in Metabolic Dysfunction-Associated Steatotic Liver Disease	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 01	Basic & Experimental 1	10170	Sachiyo Yoshio	Short-Term Exercise, But Not Bariatric Surgery, Reverses Cd4 + T-Cell Exhaustion in Severe Obesity and MASLD	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 02	Basic & Experimental 2	10083	Hitoshi Iwasaki	Spp1/cd44 Axis and Slc7a11-Mediated Ferroptosis Resistance in Poor Tumor Necrosis After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma	Friday September 18, 2026	17:36-18:06	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 02	Basic & Experimental 2	10135	Che-Yu Hsu	Cytoplasmic Pla2 Contributes to Senescence-Mediated Lipid Accumulation in Primary Human Hepatocytes	Friday September 18, 2026	17:36-18:06	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 02	Basic & Experimental 2	10101	Daisuke Minowa	Exercise Improves Sarcopenia and Metabolic Dysfunction-Associated Steatohepatitis Through Activation of Skeletal Muscle Pgc-1 <i>α</i> /sirt1 Signaling	Friday September 18, 2026	17:36-18:06	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 02	Basic & Experimental 2	10218	Erdenetsogt Dungubat	Automated Quantification of Interlobular Bile Duct Loss in Whole-Slide Liver Images Using Deep Learning in a Mouse Model of Primary Biliary Cholangitis	Friday September 18, 2026	17:36-18:06	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 02	Basic & Experimental 2	10049	Sohji Nishina	Photothermally Modulated Liposome Enabling Efficient Release of 2-Deoxy-D-Glucose Safely Displays Vigorous Antitumor Effect Against Liver Cancer	Friday September 18, 2026	17:36-18:06	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 03	Basic & Experimental 3	10209	Hiroteru Kamimura	Effects of Voluntary Wheel Running on Hepatic Tissue and Skeletal Muscle in MASH Model Mice and Underlying Mechanisms	Friday September 18, 2026	17:00-17:30	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 03	Basic & Experimental 3	10041	Monirujjaman Biswas	Unveiling Glucose-Independent and Reversible Metabolic Pathways in Metformin's Anti-Proliferative Action on Liver Cancer Cells	Friday September 18, 2026	17:00-17:30	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 03	Basic & Experimental 3	10189	Tatsuo Kanda	Cabozantinib Could Inhibit Hepatitis a Replication in Human Hepatocytes	Friday September 18, 2026	17:00-17:30	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 03	Basic & Experimental 3	10259	Masashi Nakamura	Smyd2 Regulates Lymph Node Metastasis Derived from Intrahepatic Cholangiocellular Carcinoma Through Ccr7-Dependent Chemotaxis	Friday September 18, 2026	17:00-17:30	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 03	Basic & Experimental 3	10252	Tomoko Koda	Preliminary Analysis of Hepatic Pgc-1 <i>α</i> Expression Following Melatonin Administration in an Adenine-Induced Chronic Kidney Disease Mouse Model	Friday September 18, 2026	17:00-17:30	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 04	Basic & Experimental 4	10097	Yutao Dong	A Humanized Liver Mouse Model Supporting Hepatitis a Virus Infection and Antiviral Evaluation	Friday September 18, 2026	17:30-18:00	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 04	Basic & Experimental 4	10377	Sotaro Kurano	Spatial Transcriptomic Identification of an Inflammatory Tumor Microenvironment in HBsAg Transgenicmice with Diet-Induced MASH	Friday September 18, 2026	17:30-18:00	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 04	Basic & Experimental 4	10290	Yi-Hsuan Li	Exercise-Induced Changes in Serum Extracellular Vesicle-Associated Oxidative Status in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	Friday September 18, 2026	17:30-18:00	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 04	Basic & Experimental 4	10089	Anand Krishna Singh	Therapeutic Synergy of Sestrin Ampk Pathway and Sglt 2 Inhibitors from Soybean Glycine Max in Type 2 Diabetes Associated Hepatic Dysfunction	Friday September 18, 2026	17:30-18:00	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 04	Basic & Experimental 4	10014	Wei-Yu Kao	Sustained High-Fat Diet Intake Differentially Regulates Hepatic Lipophagy and Metabolic Adaptation after Bariatric Surgery in Obese Rats	Friday September 18, 2026	17:30-18:00	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 05	Basic & Experimental 5	10139	Bao V Tran	Therapeutic Potential of Recombinant Human Cytoglobin in Acetaminophen-Induced Hepatotoxicity: Evidence from in Vivo and Transcriptomic Analyses	Friday September 18, 2026	18:00-18:30	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 05	Basic & Experimental 5	10336	Mitsuki Ishida	Porto-Sinusoidal Vascular Disorder as a Cause of Non-Cirrhotic Portal Hypertension in a Patient with Rheumatoid Arthritis on Long-Term Methotrexate and Igaratimod	Friday September 18, 2026	18:00-18:30	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 05	Basic & Experimental 5	10028	Bibek Thapa	Community-Led Harm Reduction Pathways to End Hepatitis C Elimination Barriers Among People Who Use Drugs in Nepal	Friday September 18, 2026	18:00-18:30	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 05	Basic & Experimental 5	10227	Yu-Ching Huang	Tryptophan Metabolites Attenuates Liver Fibrosis by Modulating Hepatic Stellate Cell Status and Restoring Mitochondrial Dynamics in Masld/mash	Friday September 18, 2026	18:00-18:30	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 05	Basic & Experimental 5	10116	Minsun Kim	Machine Learning Model for HCC Risk Prediction in MASLD Patients Using Fibroscan and Emr Data	Friday September 18, 2026	18:00-18:30	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 06	Basic & Experimental 6	10233	Kotaro Kumagai	Gpnmb Drives Macrophage-Mediated Immune Suppression and T Cell Dysfunction in Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 06	Basic & Experimental 6	10351	Wu Chang	Hepatocyte-Specific Flcn Deficiency Attenuates Mash-Associated Hepatocarcinogenesis	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 06	Basic & Experimental 6	10206	Nisrin Binti Abd Kadir	Pesticide-Induced Oxidative Stress in Rice (Oryza Sativa L Cv Mr263): a Possible Link to Hepatotoxic Risk in Consumers	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 06	Basic & Experimental 6	10369	Pardeep Kumar	Machine Learning Based Analysis of Epigenetic Signatures in Pediatric Malnutrition: Histone Modification Patterns Associated with Liver Dysfunction and Growth Outcomes	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 06	Basic & Experimental 6	10286	Mitsuki Ishida	Methotrexate-Induced Portosinusoidal Vascular Disorder Presenting with Splenomegaly and Periumbilical Varices in a Rheumatoid Arthritis Patient: Confirmation by Drug-Induced Lymphocyte Stimulation Test	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 07	Basic & Experimental 7	10030	Jie Yu	Betaine Homocysteine Methyltransferase Attenuates Metabolic Dysfunction-Associated Steatohepatitis by Inhibiting Notch4-Hes1 Pathway	Saturday September 19, 2026	15:30-15:54	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 07	Basic & Experimental 7	10071	Bui Tam Chi Nguyen	Single-Cell Transcriptomic Analysis Identifies Ccbe1 as a Novel Hsc Quiescence Marker Restored by Cytoglobin in Liver Fibrosis	Saturday September 19, 2026	15:30-15:54	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 07	Basic & Experimental 7	10070	Saima Mushtaq	Targeting Hbx in Hbv-Related HCC Through In-Silico and Crispr Approaches	Saturday September 19, 2026	15:30-15:54	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 07	Basic & Experimental 7	10112	Suzuki Takuto	Impact of Dgk ζ Deficiency on Liver Fibrosis in a MASLD Mouse Model	Saturday September 19, 2026	15:30-15:54	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 08	HCC 1	10065	Shih-Chieh Chien	Dynamic Change of New-Generation Tumor Markers in Predicting Recurrence of Hepatocellular Carcinoma Following Curative Treatment	Friday September 18, 2026	17:00-17:30	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 08	HCC 1	10348	Hung Chih Chiu	Real-World Outcomes of First-Line Stride for Unresectable HCC	Friday September 18, 2026	17:00-17:30	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 08	HCC 1	10120	Hironao Okubo	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients with Unresectable Hepatocellular Carcinoma in Early Clinical Practice: a Multicenter Analysis	Friday September 18, 2026	17:00-17:30	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 08	HCC 1	10372	Vikas Sharma	Telemedicine Based Supportive Oncology for Managing Sleep Disturbance and Anxiety in Pediatric Liver Cancer	Friday September 18, 2026	17:00-17:30	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 08	HCC 1	10168	Tingyu Lin	Gastrointestinal Bleeding Risk and the Value of Endoscopic Assessment in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab	Friday September 18, 2026	17:00-17:30	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 09	HCC 2	10201	Masakuni Tateyama	Development of Hepatocellular Carcinoma After the Eradication of Hepatitis C Virus by Direct-Acting Antivirals and Outcome of the Patients with Sustained Virological Response	Friday September 18, 2026	17:30-18:06	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 09	HCC 2	10374	Haruhiko Takeda	Clinical Utility and Limitations of Comprehensive Genomic Profiling in Immunotherapy-Treated Advanced Hepatocellular Carcinoma: Insights from Multi-Omics Analysis	Friday September 18, 2026	17:30-18:06	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 09	HCC 2	10131	Yu Akazawa	Long-Term Prognostic Impact of Immune-Mediated Hepatitis in Patients Receiving Immune Checkpoint Inhibitors	Friday September 18, 2026	17:30-18:06	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 09	HCC 2	10184	Daiki Maeda	Early AFP Reduction Predicts Conversion Therapy and Long-Term Survival in Br2 Hepatocellular Carcinoma	Friday September 18, 2026	17:30-18:06	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 09	HCC 2	10302	Yuki Minetoma	Durable Drug-Free Complete Response to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma with Major Portal Vein Invasion After Managing Portal Hypertension: a Case-Based Cohort Analysis	Friday September 18, 2026	17:30-18:06	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 09	HCC 2	10152	Hery Djagat Purnomo	One in Five Hepatocellular Carcinomas Are Afp-Negative: Clinical Characteristics and Prognostic Implications from Six-Year Indonesian Study	Friday September 18, 2026	17:30-18:06	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 10	HCC 3	10338	Makoto Chuma	Clinical Significance of Circulating Biomarkers of Immune Checkpoint Molecules with Atezolizumab Plus Bevacizumab Therapy in Unresectable Hepatocellular Carcinoma	Friday September 18, 2026	18:06-18:36	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 10	HCC 3	10350	Erdenebayar Gonchig	Patterns of Extrahepatic Metastasis in Hepatocellular Carcinoma	Friday September 18, 2026	18:06-18:36	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 10	HCC 3	10231	Takao Shimizu	Real-World Outcomes of Short-Course Len-Tace Sequential Therapy for Intermediate-Stage Hepatocellular Carcinoma	Friday September 18, 2026	18:06-18:36	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 10	HCC 3	10173	Hidekazu Yamamoto	Clinical Outcomes of Conversion Surgery Following Immune Checkpoint Inhibitor Therapy in Patients with Advanced Hepatocellular Carcinoma	Friday September 18, 2026	18:06-18:36	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 10	HCC 3	10176	Takeshi Matsui	Clinical Characteristics of Patients with Spontaneous Rupture of Hepatocellular Carcinoma at a Single Center	Friday September 18, 2026	18:06-18:36	18:30	18:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 11	HCC 4	10332	Daigo Mamitsuka	Clinical Outcomes of Durvalumab Plus Tremelimumab for Advanced Hepatocellular Carcinoma: a Case Series Highlighting an Exceptional Response in Concomitant Mss Colorectal Cancer	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 11	HCC 4	10246	Hiroaki Matsumoto	Early Real-World Experience with Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma: a Single-Center Experience in Japan	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 11	HCC 4	10278	Yoshinari Asaoka	Efficacy and Severe Iraes of First-Line Nivolumab Plus Ipilimumab for Advanced Hepatocellular Carcinoma: a Case Series	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 11	HCC 4	10216	Oyunselenge B	Association of Hba1c with Liver Steatosis and Fibrosis	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 11	HCC 4	10075	Habib M Sazzad	Observation of Six Months Outcome of Hepatocellular Carcinoma Patients with First Line Systemic Treatment on the Basis of Etiology	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 11	HCC 4	10080	Hideaki Miyamoto	Regimen-Specific Immune-Related Adverse Event Profiles in Patients Receiving Io-Io Combination Therapy	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 12	HCC 5	10314	Jun Arai	Efficacy of Scheduled Lenvatinib Plus TACE for Intermediate-Stage, Tace-Unsuitable Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 12	HCC 5	10025	Mi Na Kim	The Impact of Alcohol Consumption on the Risk of Hepatocellular Carcinoma Across Different Age Groups: a Nationwide Cohort Study	Saturday September 19, 2026	15:00-15:36	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 12	HCC 5	10072	Minjeong Kang	Efficacy and Safety of Adding Radiotherapy to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis	Saturday September 19, 2026	15:00-15:36	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 12	HCC 5	10234	Miuzki Endo	Long-Term Investigation of Hepatocarcinogenesis in Patients with Type 2 Diabetes Mellitus: a 20-Year Prospective Cohort Study	Saturday September 19, 2026	15:00-15:36	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 12	HCC 5	10291	Asahiro Morishita	PD-L1 Gene Polymorphisms as Predictive Biomarkers for Immune Checkpoint Inhibitor Combination Therapy in Unresectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 12	HCC 5	10371	Yoshie Kadota	Radiofrequency Ablation for Suspected Hepatocellular Carcinoma in a Patient with Hepatitis C-Related Cirrhosis and Situs Viscerum Inversus After the Fontan Procedure: a Case Report	Saturday September 19, 2026	15:00-15:36	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 13	HCC 6	10088	Ko Hashimoto	Early Changes in AFP and Dep Predict Response to Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma: a Multicenter Retrospective Study	Saturday September 19, 2026	15:36-16:12	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 13	HCC 6	10298	Sho Ijuin	Prognostic Impact of Nutritional Assessment Markers in Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab	Saturday September 19, 2026	15:36-16:12	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 13	HCC 6	10199	Hironao Okubo	Treatment of Unresectable Hepatocellular Carcinoma with Cabozantinib in the Era of Immunotherapy: Importance of Treatment Sequence	Saturday September 19, 2026	15:36-16:12	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 13	HCC 6	10310	Keisuke Koroki	Comparative Analysis of Immune-Mediated Adverse Events and Early Efficacy of Durvalumab + Tremelimumab and Nivolumab + Ipilimumab in Advanced Hepatocellular Carcinoma	Saturday September 19, 2026	15:36-16:12	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 13	HCC 6	10153	Toshinori Toyota	Treatment-Related Skeletal Muscle Loss During Systemic Therapy: a Multicenter Comparison of Atezolizumab Bevacizumab and Lenvatinib in Unresectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:36-16:12	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 13	HCC 6	10261	Riku Nakashima	Clinical Outcomes of Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma: a Single-Center Retrospective Study	Saturday September 19, 2026	15:36-16:12	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 14	HCC 7	10001	Hiraoka Atsushi	Interaction Between Simplified Balad Score and Treatment Efficacy of Immune Checkpoint Inhibitor Regimens in Unresectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 14	HCC 7	10320	Shohei Shiota	Characteristics of Ruptured Liver Cancer Cases Experienced over the Past Year	Saturday September 19, 2026	15:00-15:36	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 14	HCC 7	10217	Amarsanaa Jazag	A-Hoc Study on Patients under Surveillance for Liver Cancer in Mongolia	Saturday September 19, 2026	15:00-15:36	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 14	HCC 7	10214	Anujin Chinzorig	Mongolian National University of Medical Sciences	Saturday September 19, 2026	15:00-15:36	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 14	HCC 7	10346	Kenta Yamamoto	Gut Microbiota-Enhanced Survival Stratification in Hypervascular Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 14	HCC 7	10150	Satoshi Narahara	The Harmony Index: an Early Predictor of Primary Resistance to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 15	HCC 8	10253	Kyoko Oura	Clinical Impact of Sarcopenia Diagnosed Using Handgrip Strength and Skeletal Muscle Index in Patients with Hepatocellular Carcinoma Receiving Combination Immunotherapy	Saturday September 19, 2026	15:36-16:12	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 15	HCC 8	10322	Akihiro Deguchi	Clinical Impact of Incorporating New Fp Hepatic Arterial Infusion Chemotherapy into the Sequential Treatment Strategy After Combination Immunotherapy for Unresectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:36-16:12	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 15	HCC 8	10118	Chinatsu Nishioka	Real-World Efficacy and Safety of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma: a Multicenter Cohort Study	Saturday September 19, 2026	15:36-16:12	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 15	HCC 8	10316	Yutaro Hori	Verification of the Therapeutic Effect of Dual Immune Checkpoint Inhibitor for Advanced Hepatocellular Carcinoma Using Previously Reported Treatment Effect Predictors	Saturday September 19, 2026	15:36-16:12	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 15	HCC 8	10042	Monirujjaman Biswas	Efficient Deep Learning Framework for Nucleus Segmentation from the Histopathological Images in Liver Cancer	Saturday September 19, 2026	15:36-16:12	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 15	HCC 8	10190	Ariunzaya Munkhchuluun	Comparison of Bevacizumab Treatment Outcomes by Hepatitis Virus Infection, Gender, and Age Group	Saturday September 19, 2026	15:36-16:12	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 16	Hepato-Biliary Disease 1	10352	Erdenebayar Gonchig	Patterns of Liver Metastasis from Extrahepatic Primary Malignancies	Friday September 18, 2026	17:36-18:12	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 16	Hepato-Biliary Disease 1	10040	Monirujjaman Biswas	Exploratory and Predictive Analytics of Covid-19's Impact on Liver Cancer Outcomes	Friday September 18, 2026	17:36-18:12	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 16	Hepato-Biliary Disease 1	10368	Pardeep Kumar	Agricultural Exposure to Organic Fungicides and Herbicides and the Risk of Cholangiocarcinoma in Rural Agricultural Workers	Friday September 18, 2026	17:36-18:12	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 16	Hepato-Biliary Disease 1	10069	Saima Mushtaq	Viral Persistence in Hepatitis-Associated Hepatocellular Carcinoma: Translational Evidence from Liver Tissues	Friday September 18, 2026	17:36-18:12	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 16	Hepato-Biliary Disease 1	10255	Shuntaro Obi	Adding Afp-L3 and Dcp to AFP Enables Detection Very Small HCC: Validation with A-Hoc Study	Friday September 18, 2026	17:36-18:12	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 16	Hepato-Biliary Disease 1	10066	Tagayasu Yoshiyuki	S100p Immunohistochemistry Underpins Prognostic and Molecular Stratification in Intrahepatic Cholangiocarcinoma	Friday September 18, 2026	17:36-18:12	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 17	Hepato-Biliary disease 2	10272	Hiroumi Akita	Factors Associated with Long-Term Survival in Intrahepatic Cholangiocarcinoma: a Single-Center Real-World Analysis	Saturday September 19, 2026	15:00-15:24	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 17	Hepato-Biliary disease 2	10136	Tomoaki Yoh	Evolution of Treatment Strategies and the Impact of Major Pathological Response in Borderline Resectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:24	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 17	Hepato-Biliary disease 2	10331	Tomoaki Emori	Efficacy, Safety, and Genomic Profiling of Gcd/gcp Therapy for Unresectable Intrahepatic Cholangiocarcinoma: a Real-World Study	Saturday September 19, 2026	15:00-15:24	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 17	Hepato-Biliary disease 2	10329	Tomotake Shirono	Treatment Outcomes and Prognostic Analysis in Unresectable Intrahepatic Cholangiocarcinoma: a Multicenter Retrospective Study Using Real-World Data	Saturday September 19, 2026	15:00-15:24	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 18	Hepato-Biliary disease 3	10367	Pardeep Kumar	Diagnostic Relevance of Neutrophil Gelatinase-Associated Lipocalin in Cholangiocarcinoma and Biliary Tract Cancers Among Elderly Patients	Saturday September 19, 2026	15:24-15:54	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 18	Hepato-Biliary disease 3	10043	Monirujjaman Biswas	Diagnostic Approach to Histomorphological and Immunohistochemical Spectrum of Metastatic Liver Lesions	Saturday September 19, 2026	15:24-15:54	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 18	Hepato-Biliary disease 3	10107	Keita Shirahata	Cholangioscopy for Intrahepatic Iopn with Invasive Carcinoma: a Case Report	Saturday September 19, 2026	15:24-15:54	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 18	Hepato-Biliary disease 3	10140	Kentaro Sato	A Diagnostically Challenging Case of Intrahepatic Cholangiocarcinoma with Surrounding Peribiliary Cysts	Saturday September 19, 2026	15:24-15:54	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 18	Hepato-Biliary disease 3	10171	Naoshi Odagiri	Association of Serum Full-Length Glypican-3 with Clinical Outcomes in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab	Saturday September 19, 2026	15:24-15:54	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 19	Diagnosis (Imaging & Biomarkers)	10095	Beta Canina Harlyjoy	Vascular Remodelling During Liver Fibrosis Progression and Regression	Saturday September 19, 2026	15:54-16:24	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 19	Diagnosis (Imaging & Biomarkers)	10299	Michitaka Matsuda	Intratumor Immunofibrosis Profile Associated with Hepatocellular Carcinoma Recurrence	Saturday September 19, 2026	15:54-16:24	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 19	Diagnosis (Imaging & Biomarkers)	10114	Yuzuru Sakamoto	Serum Soluble Siglec-5 Is a Prognostic Biomarker in Patients with Hepatocellular Carcinoma	Saturday September 19, 2026	15:54-16:24	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 19	Diagnosis (Imaging & Biomarkers)	10215	Erdenebayar Gonchig	Association Between Glycemic Control (Hba1c) and Liver Transaminase Levels (ALT and AST)	Saturday September 19, 2026	15:54-16:24	16:12	16:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 19	Diagnosis (Imaging & Biomarkers)	10210	Khongorzul E	Correlation Between Liver Biomarkers and Hemoglobin Levels	Saturday September 19, 2026	15:54-16:24	16:18	16:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 20	Hepatitis & Chronic Liver Disease 1	10305	Akio Moriya	Factors Associated with Alanine Aminotransferase Improvement After Initiation of Tirzepatide in Patients with Type 2 Diabetes	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 20	Hepatitis & Chronic Liver Disease 1	10328	Minkyoung Gu	Ai-Based Integrative Analysis of Alcohol Associated Liver Injury	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 20	Hepatitis & Chronic Liver Disease 1	10323	Ariunaa Baljinnyam	The Effect of Semaglutide on Weight Loss and Liver Fat Reduction in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 20	Hepatitis & Chronic Liver Disease 1	10244	Tatia Khachidze	A Narrative Review of the Diagnostic Performance of Non-Invasive Scoresfor Predicting Fibrosis in MaflD	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 20	Hepatitis & Chronic Liver Disease 1	10177	Satoru Kakizaki	The Fib-3 Index Outperforms Fib-4 and Shows Comparable Prognostic Performance to Amap and Meld in Patients with Hepatic Encephalopathy Receiving Rifaximin: a Multicenter Retrospective Analysis	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 20	Hepatitis & Chronic Liver Disease 1	10342	Makiko Taniai	Clinical Aspects of Hepatocellular Carcinoma in Autoimmune Liver Diseases	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 21	Hepatitis & Chronic Liver Disease 2	10262	Xin Zheng	Identification of Novel Antiviral Agent Against Hepatitis a Virus Replication	Friday September 18, 2026	17:36-18:06	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 21	Hepatitis & Chronic Liver Disease 2	10276	Doaa A Abo Elwafa	Enhanced Suppression of Hepatitis D Virus Infection by a Newly Developed Rxr Agonist Targeting Ntcp Mediated Viral Entry	Friday September 18, 2026	17:36-18:06	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 21	Hepatitis & Chronic Liver Disease 2	10220	Amarsanaa Jazag	Study on Patients Undergoing Triple Therapy for Liver Steatosis in Mongolia	Friday September 18, 2026	17:36-18:06	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 21	Hepatitis & Chronic Liver Disease 2	10024	Mi Na Kim	Effect of Diabetes on the Risk of Fibrosis Progression in Patients with Chronic Hepatitis B	Friday September 18, 2026	17:36-18:06	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 21	Hepatitis & Chronic Liver Disease 2	10195	Harsha Vardhan Manjunatha	Efficacy and Safety of Combining Immune Checkpoint Inhibitors with Transarterial Radioembolization in Advanced/unresectable Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis	Friday September 18, 2026	17:36-18:06	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 22	Hepatitis & Chronic Liver Disease 3	10204	Tatsunori Kondo	A Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome Associated with Immune Thrombocytopenia	Friday September 18, 2026	18:06-18:36	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 22	Hepatitis & Chronic Liver Disease 3	10269	Misaki Matsui	Radiotherapy (Rt) for Hepatocellular Carcinoma at Our Institution	Friday September 18, 2026	18:06-18:36	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 22	Hepatitis & Chronic Liver Disease 3	10013	Vu Van Khien	Efficacy and Safety of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Vietnam	Friday September 18, 2026	18:06-18:36	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 22	Hepatitis & Chronic Liver Disease 3	10145	Ruba Chakma	Seroprevalence of Hepatitis E Virus Exposure Among Patients with Hepatocellular Carcinoma in Chiang Mai, Thailand	Friday September 18, 2026	18:06-18:36	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 22	Hepatitis & Chronic Liver Disease 3	10172	Anfal Abdelazeim Abbass Taifour	Hemochromatosis Presenting with Severe Jaundice, Arthralgia, Amenorrhea, and Bronze Skin Pigmentation Mimicking Acute Viral Hepatitis :a Case Report	Friday September 18, 2026	18:06-18:36	18:30	18:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 23	Hepatitis & Chronic LiverDisease 4	10144	Rama_maleakhi Saragih	Differential Associations of Hepatic Steatosis, Metabolic Dysfunction, and Steatohepatitis with Hepatocellular Carcinoma Risk in Chronic Hepatitis B: a Systematic Review and Meta-Analysis	Saturday September 19, 2026	15:00-15:36	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 23	Hepatitis & Chronic LiverDisease 4	10063	Md Farhad Hossen	Perceptions and Awareness of Non-Alcoholic Fatty Liver Disease at the Community Level in Bangladesh a Cross-Sectional Study	Saturday September 19, 2026	15:00-15:36	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 23	Hepatitis & Chronic LiverDisease 4	10166	Harshita Dubey	Chemotherapy Induced Hepatic Steatosis in Ovarian Cancer	Saturday September 19, 2026	15:00-15:36	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 23	Hepatitis & Chronic LiverDisease 4	10004	Eihmile Kreistein N Salgado	The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Using Sonographic Qualitative Assessment Among Filipino Patients with Metabolic Syndrome in a Tertiary Hospital in Iloilo City: a Pilot Study	Saturday September 19, 2026	15:00-15:36	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 23	Hepatitis & Chronic LiverDisease 4	10373	Ankush Kumar	Central Obesity, Insulin Resistance, and Ldl Cholesterol in Middle-Aged Women with Nonalcoholic Fatty Liver Disease: Implications for Progression to Advanced Liver Disease	Saturday September 19, 2026	15:00-15:36	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 23	Hepatitis & Chronic LiverDisease 4	10019	Arjun Maria	Development and Validation of an AI Driven Convolutional Neural Network for Automated Stool Colour Classification to Facilitate Early Diagnosis of Biliary Atresia	Saturday September 19, 2026	15:00-15:36	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 24	Hepatitis & Chronic LiverDisease 5	10044	Natsumi Tsukano	Steatotic Liver Disease During Steroid Therapy in Patients with Autoimmune Hepatitis and Its Associated Factors	Saturday September 19, 2026	15:36-16:06	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 24	Hepatitis & Chronic LiverDisease 5	10053	Demver P Gomez	Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in Hbeag-Negative Chronic Hepatitis B: Meta-Analysis of Randomized Trials	Saturday September 19, 2026	15:36-16:06	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 24	Hepatitis & Chronic LiverDisease 5	10363	Keisuke Ishigami	Igm-Positive Plasma Cell Tubulointerstitial Nephritis in Patients Diagnosed with Autoimmune Hepatitis and Elevated Serum Igm Levels	Saturday September 19, 2026	15:36-16:06	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 24	Hepatitis & Chronic LiverDisease 5	10222	Erdenebayar Gonchig	Age-Specific Prevalence of Viral Hepatitis in Mongolia	Saturday September 19, 2026	15:36-16:06	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 24	Hepatitis & Chronic LiverDisease 5	10109	Anand Krishna Singh	Synergistic Effects of Withania Somnifera Alkaloid Extract and Metformin on Hepatic Ultrastructure and Biochemistry in a NAFLD Model	Saturday September 19, 2026	15:36-16:06	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 25	Hepatitis & Chronic LiverDisease 6	10183	Aswanth Ks	Calfan Syndrome: an Unusual Cause of Infantile Acute-On-Chronic Liver Failure	Saturday September 19, 2026	16:06-16:36	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 25	Hepatitis & Chronic LiverDisease 6	10054	Yasuhiko Nakao	Noninvasive Prediction of Serum Bilirubin via Scleral Color Analysis: Clinical Validation of the Lab B-Channel as a Practical Biomarker for Jaundice Screening	Saturday September 19, 2026	16:06-16:36	16:12	16:18	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 25	Hepatitis & Chronic LiverDisease 6	10022	Khiem K Pham	Primary Biliary Cholangitis in Vietnam: Heterogeneous Biochemical Patterns and a High Proportion of Ama-Negative Cases	Saturday September 19, 2026	16:06-16:36	16:18	16:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 25	Hepatitis & Chronic LiverDisease 6	10192	Erdenebayar Gonchig	Declining Trends of Hepatitis Virus Prevalence in Mongolia: an Analysis Based on Early Detection Data	Saturday September 19, 2026	16:06-16:36	16:24	16:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 25	Hepatitis & Chronic LiverDisease 6	10334	Hyunjin Jeong	Loss of Erdj5 Drives Sorafenib Resistance in Hepatocellular Carcinoma by Regulating Gpx4-Dependent Ferroptosis	Saturday September 19, 2026	16:06-16:36	16:30	16:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 26	Clinical and Translational Hepatology 1	10211	Ryoko Asari	Early Real-World Experience Integrating Point-Of-Care Hbeag-Hs Rapid Testing into Routine Antenatal Services for HBV Pmtct in the Gambia	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 26	Clinical and Translational Hepatology 1	10287	Kazunari Tanaka	Clinical Impact of Beta-D-Glucan Positivity in Patients with Acute Liver Failure	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 26	Clinical and Translational Hepatology 1	10020	Arjun Maria	Impact of Continuous Renal Replacement Therapy on Survival and Ammonia Clearance in Hepatitis a Virus Associated Pediatric Acute Liver Failure with Advanced Hepatic Encephalopathy: a Two-Centre Retrospective Cohort Analysis	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 26	Clinical and Translational Hepatology 1	10266	Shunhei Yamashina	Cathepsin L Inhibitor Enhances Liver Regeneration in Fibrotic Liver	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 26	Clinical and Translational Hepatology 1	10319	Sourav Kumar Chakraborty	TACE Plus Lenvatinib Improves Objective Response and Downstaging Within Ucsf Criteria in Treatment-Naive Unresectable HCC: a Comparative Study	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 26	Clinical and Translational Hepatology 1	10165	Asgar Ali	Pten as a Diagnostic and Prognostic Biomarker in Periampullary Cancer: a Tissue-Based Molecular Study from India	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 27	Clinical and Translational Hepatology 2	10091	Takahiro Mizuta	Impact of Hepatic Steatosis on Lsm-Based Cirrhosis Assessment and Ckd Risk Stratification in MASLD	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 27	Clinical and Translational Hepatology 2	10229	Hirayuki Enomoto	Hepatoma-Derived Growth Factor as a Potential Therapeutic Target for Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 27	Clinical and Translational Hepatology 2	10055	Mohammad Khairul Basher	Comparison of Epidemiological, Biochemical, and Radiological Characteristics Between Viral and Non-Viral Etiology of Hepatocellular Carcinoma Patients	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 27	Clinical and Translational Hepatology 2	10308	Fatimah Abd Kadir	Photocatalytic Degradation of Methylene Blue to Mitigate Liver Disease: a Step Toward Sustainable Wastewater Treatment	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 27	Clinical and Translational Hepatology 2	10223	Tomoko Aoki	Stromal-Rich Tumor Immune Microenvironment in Fdg-Pet-Positive Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 28	MASLD/ MAFLD and ALD 1	10056	Trang Diep Thanh Le	Feasibility of Deep Learning-Based Automated Histopathological Scoring for Metabolic Dysfunction-Associated Steatohepatitis (MASH): a Pilot Study	Friday September 18, 2026	17:36-18:12	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 28	MASLD/ MAFLD and ALD 1	10010	Eisuke Murakami	Association of the Elf Score with Liver-Related Complications and Cardiovascular Events in Metabolic Dysfunction-Associated Steatohepatitis	Friday September 18, 2026	17:36-18:12	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 28	MASLD/ MAFLD and ALD 1	10343	Chia-Yang Li	Genomic Signatures Associated with Different Stages of Fibrosis in MASLD and Semaglutide Treatment Effects	Friday September 18, 2026	17:36-18:12	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 28	MASLD/ MAFLD and ALD 1	10035	Taketo Fukuoka	A Novel Abca1 Mutation in Shrsp5/dmcr Rats Promotes MASH via Hepatic Free Cholesterol Overload and Nlrp3 Inflammasome Activation	Friday September 18, 2026	17:36-18:12	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 28	MASLD/ MAFLD and ALD 1	10330	Jumpei Okamura	Impact of Alcohol Intake on the Efficacy of a Moderate-Carbohydrate Diet in Patients with MASLD	Friday September 18, 2026	17:36-18:12	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 28	MASLD/ MAFLD and ALD 1	10254	Takemi Akahane	Serum Cytokeratin-18 Fragment Refines Fib-4 Index-based Risk Stratification for At-Risk MASH	Friday September 18, 2026	17:36-18:12	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 29	MASLD/ MAFLD and ALD 2	10137	Lian-Wang Cai	Extracellular Vesicle Biomarkers Enhance Machine Learning Classification of Obese and Lean Metabolic Dysfunction-Associated Steatotic Liver Disease	Friday September 18, 2026	18:12-18:48	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 29	MASLD/ MAFLD and ALD 2	10347	Adinda Amalia	Beyond Baveno Vii Non-Invasive Criteria: Eus-Ppg Confirmed Clinically Significant Portal Hypertension in MASLD with Low Liver Stiffness	Friday September 18, 2026	18:12-18:48	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 29	MASLD/ MAFLD and ALD 2	10219	Tomomi Kogiso	Association Between Hepatic Steatosis and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B	Friday September 18, 2026	18:12-18:48	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 29	MASLD/ MAFLD and ALD 2	10017	Tomohide Kurahashi	Early Weight Response Identifies a High-Risk Phenotype in MASLD Patients Treated with Tirzepatide	Friday September 18, 2026	18:12-18:48	18:30	18:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 29	MASLD/ MAFLD and ALD 2	10186	Meti Metiani	Pnpla3 Rs738409 as a Genetic Driver of Mafld in Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis	Friday September 18, 2026	18:12-18:48	18:36	18:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 29	MASLD/ MAFLD and ALD 2	10158	Sae Kyung Joo	Sex-Specific Determinants of Fibrosis Progression in MASLD: the Role of Menopause and Endogenous Estrogen Exposure	Friday September 18, 2026	18:12-18:48	18:42	18:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 30	MASLD/ MAFLD and ALD 3	10167	Soon Kyu Lee	Swe Performs Comparably to Vete in a Fib-4 Based Two-Step Risk Stratification Strategy for MASLD	Saturday September 19, 2026	15:30-16:00	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 30	MASLD/ MAFLD and ALD 3	10359	Dan Nakano	An Association of Covert Hepatic Encephalopathy with Non-Elderly and MASLD in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Data-Mining Analyses	Saturday September 19, 2026	15:30-16:00	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 30	MASLD/ MAFLD and ALD 3	10260	Ryotaro Sakamori	Clinical Event Risk in Patients with MASLD: Findings from a Prospective Multicenter Registry	Saturday September 19, 2026	15:30-16:00	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 30	MASLD/ MAFLD and ALD 3	10007	Hana Park	Differential Cancer Risks and Noninvasive Predictors in MASLD, Metald, and Ald: a Longitudinal Analysis	Saturday September 19, 2026	15:30-16:00	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 30	MASLD/ MAFLD and ALD 3	10087	Ryohei Yoshino	Inhibition of Polyamine Oxidation Modulates Hepatic Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease	Saturday September 19, 2026	15:30-16:00	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 31	MASLD/ MAFLD and ALD 4	10046	Kaede Fujita	Imeglimin in MASLD with Type 2 Diabetes: a Pilot Study on Hepatic and Metabolic Improvements	Saturday September 19, 2026	15:00-15:36	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 31	MASLD/ MAFLD and ALD 4	10142	Inas Karimi	Hepatorenal Crosstalk in Metabolic Syndrome: Nafld/masld as an Independent Risk Factor for Ckd	Saturday September 19, 2026	15:00-15:36	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 31	MASLD/ MAFLD and ALD 4	10067	Jacqueline Kwa	Raising MASLD Awareness for Early Prevention: a Public Health Education Initiative in Singapore	Saturday September 19, 2026	15:00-15:36	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 31	MASLD/ MAFLD and ALD 4	10130	Hideto Yuruki	Utility of the Fatty Liver Index as a Predictor of Hepatic Steatosis in Patients with Ald/metald	Saturday September 19, 2026	15:00-15:36	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 31	MASLD/ MAFLD and ALD 4	10151	Hery Djagat Purnomo	Altered Gut Microbial Taxa Are Associated with Metabolically Associated Fatty Liver Disease in Indonesian Adults : a Preliminary Study	Saturday September 19, 2026	15:00-15:36	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 31	MASLD/ MAFLD and ALD 4	10245	Tatia Khachidze	The Role of Probiotics and Prebiotics in the Management of MASLD: Aclinical Perspective	Saturday September 19, 2026	15:00-15:36	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 32	MASLD/ MAFLD and ALD 5	10379	Sung Jun Park	Comparison of Effectiveness Between Phentermine/topiramate and Liraglutide in Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	Saturday September 19, 2026	15:36-16:12	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 32	MASLD/ MAFLD and ALD 5	10380	Mana Takano	Comparison of Liver Fibrosis Assessment by Shear Wave Elastography and Liver Biopsy	Saturday September 19, 2026	15:36-16:12	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 32	MASLD/ MAFLD and ALD 5	10366	Takashi Nishimura	Prediction of Hepatocellular Carcinoma Development in Patients with Alcohol-Related Liver Disease Using the Fib-3 Index, Fib-4 Index, and Vibration-Controlled Transient Elastography	Saturday September 19, 2026	15:36-16:12	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 32	MASLD/ MAFLD and ALD 5	10293	Junichi Hanatani	Efficacy and Safety of Nalmefene on Alcohol Consumption, Liver Function, and Gut Microbiota in Alcohol-Related Liver Disease	Saturday September 19, 2026	15:36-16:12	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 32	MASLD/ MAFLD and ALD 5	10068	Masafumi Haraguchi	Impact of Extracellular Fluid Retention on Bioelectrical Impedance-Based Muscle Mass Assessment in Patients with Steatotic Liver Disease-Related Cirrhosis: a Ct-Validated Study	Saturday September 19, 2026	15:36-16:12	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 32	MASLD/ MAFLD and ALD 5	10015	Vu Van Khien	Yttrium-90 Transarterial Radioembolization for Hepatocellular Carcinoma: Summary of 10 Years from Two Centers in Vietnam	Saturday September 19, 2026	15:36-16:12	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 33	Hepatitis B 1	10161	Kengo Watanabe	Differential Impact of Steatotic Liver Disease on Liver Fibrosis Progression According to Hepatitis B Virus DNA Levels in Untreated Patients with Chronic Hepatitis B Virus Infection	Friday September 18, 2026	17:00-17:30	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 33	Hepatitis B 1	10281	Esraa Kamal	High Throughput Identification of a Potent Inhibitor of Hepatitis B Virus Infection	Friday September 18, 2026	17:00-17:30	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 33	Hepatitis B 1	10341	Taotao Yan	Antiviral Therapies Are Under-Utilized in Patients with Hepatitis B-Related Hepatocellular Carcinoma Despite Substantial Survival Benefits	Friday September 18, 2026	17:00-17:30	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 33	Hepatitis B 1	10059	Eiichi Ogawa	Long-Term Clinical Impact of MASLD After Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B	Friday September 18, 2026	17:00-17:30	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 33	Hepatitis B 1	10073	Kathryn Effendi	Implementation of the Anrs 0562s Hipocamp Study in Vietnam: an International Collaborative Pilot Study on the Prevention of Mother-To-Child Transmission of Hepatitis B Virus (HBV)	Friday September 18, 2026	17:00-17:30	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 34	Hepatitis B 2	10021	Arjun Maria	Spectrum and Clinical Impact of Liver Involvement in Children Hospitalized with Respiratory Viral Infections	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 34	Hepatitis B 2	10086	Bunga P Ramadhani	Longitudinal Assessment of Hepatitis B Virus-Specific B Cells Before and After Nucleos(t)ide Therapy in Chronic Hepatitis B Patients	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 34	Hepatitis B 2	10162	Kotaro Doi	Longitudinal Increase in Fib-4 Index and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogues: a Multicenter Study	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 34	Hepatitis B 2	10099	Yohei Shirakami	Inhibition of Indoleamine 2,3-Dioxygenase Enhances Immune Responses to a Therapeutic Vaccine for Chronic Hepatitis B	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 34	Hepatitis B 2	10317	Takashi Honda	Association Between Hepatitis B Virus Mutation Rates and Clinical Outcomes in Chronic Hepatitis B	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 35	Hepatitis B/ Virus	10093	Keisuke Amano	Diagnostic Accuracy of a Clinically Accessible Itact-Based HCV Core Antigen Assay in a Japanese Cohort	Saturday September 19, 2026	15:30-16:06	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 35	Hepatitis B/ Virus	10154	Seiichi Mawatari	Cause-Specific Standardized Mortality Ratios in Patients After HCV Eradication with Direct-Acting Antivirals	Saturday September 19, 2026	15:30-16:06	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 35	Hepatitis B/ Virus	10292	Hiroyuki Kobayashi	Community-Based Hepatitis B Virus Screening Identifies Previously Undiagnosed Patients Requiring Antiviral Therapy in a Rural Japanese Population: the Nagawa Project	Saturday September 19, 2026	15:30-16:06	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 35	Hepatitis B/ Virus	10126	Tetsuya Hosaka	Latest Profiles of Qhbsag Among Patients Continuing Long-Term Nuc Treatment in Japan	Saturday September 19, 2026	15:30-16:06	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 35	Hepatitis B/ Virus	10117	Ekram Hasanin	Global Trends in Liver Cancer Attributable to Hepatitis B: Insights from the Globalburden of Disease 2023	Saturday September 19, 2026	15:30-16:06	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 35	Hepatitis B/ Virus	10339	Naoki Yamamoto	Development of a Highly Sensitive Rapid Test for the Detection of Hepatitis B Core-Related Antigen	Saturday September 19, 2026	15:30-16:06	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 36	Liver Cirrhosis and Miscellaneous 1	10294	Masaru Muraoka	A Study Using Mre and Neuropsychological Test Subtests for Stratification of Minimal Hepatic Encephalopathy Risk	Friday September 18, 2026	17:30-18:00	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 36	Liver Cirrhosis and Miscellaneous 1	10318	Shah Emtiaz Rahman	Spleen Stiffness Outperforms Conventional Fibrosis Markers for Predicting Esophageal Varices in Cirrhosis	Friday September 18, 2026	17:30-18:00	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 36	Liver Cirrhosis and Miscellaneous 1	10326	Ryuki Hashida	Safety and Feasibility of Supervised Low-Intensity Rehabilitation in Decompensated Liver Cirrhosis	Friday September 18, 2026	17:30-18:00	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 36	Liver Cirrhosis and Miscellaneous 1	10134	Huong Tu Lam	Multidrug-Resistant Pathogens and Treatment Non-Response in Spontaneous Bacterial Peritonitis Among Cirrhotic Patients: a Cohort Study from Vietnam	Friday September 18, 2026	17:30-18:00	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 36	Liver Cirrhosis and Miscellaneous 1	10312	Chikara Ogawa	Real-World Efficacy and Safety of Avatrombopag for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Invasive Procedures	Friday September 18, 2026	17:30-18:00	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 37	Liver Cirrhosis and Miscellaneous 2	10289	Yuki Motokawa	Vwf/adamts13 Ratio Improves the Diagnosis of Sarcopenia in Patients with Liver Cirrhosis	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 37	Liver Cirrhosis and Miscellaneous 2	10295	Marco Distefano	Claire: a Zero-Code, Uncertainty-Aware Llm Agent Transforming Cirrhosis Records into Actionable Intelligence for Liver Cancer Control	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 37	Liver Cirrhosis and Miscellaneous 2	10345	Natsuko Nishiyama	Evaluation of Portal Venous Hemodynamics in Portal Hypertension Using MRI	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 37	Liver Cirrhosis and Miscellaneous 2	10203	Yasuteru Kondo	Partial Splenic Embolization Improves Hepatic Reserve and Nlr, Supporting Multidisciplinary Treatment for Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 37	Liver Cirrhosis and Miscellaneous 2	10008	Hideko Ohama	Extended Five-Year Outcomes of First-Line Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: a Multicenter Real-World Study	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 38	Liver Cirrhosis and Miscellaneous 3	10175	Ryosuke Imado	Comparison of Therapeutic Efficacy Between Rifaximin and L-Carnitine for Hyperammonemia in Liver Cirrhosis: a Multicenter Retrospective Study Focusing on Long-Term Event Prevention	Saturday September 19, 2026	15:30-16:06	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 38	Liver Cirrhosis and Miscellaneous 3	10196	Yoji Ishizu	Association of Neuropsychological Test Abnormalities, Polypharmacy, and Liver Functional Reserve with Medication Understanding in Patients with Liver Disease	Saturday September 19, 2026	15:30-16:06	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 38	Liver Cirrhosis and Miscellaneous 3	10106	Minji Kim	Independent Association Between Serum Mac-2 Binding Protein Glycosylation Isomer and Fibroscan-Measured Liver Stiffness	Saturday September 19, 2026	15:30-16:06	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 38	Liver Cirrhosis and Miscellaneous 3	10364	Zannatul Habiba	Beyond Routine Blood Counts: Neutrophil-To-Lymphocyte Ratio as a Simple Predictor of Liver Cirrhosis Severity a Cross-Sectional Study from Bangladesh	Saturday September 19, 2026	15:30-16:06	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 38	Liver Cirrhosis and Miscellaneous 3	10064	Manabu Hayashi	Diabetes Mellitus and Prognosis in Cirrhotic Patients Experienced Overt Hepatic Encephalopathy	Saturday September 19, 2026	15:30-16:06	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 38	Liver Cirrhosis and Miscellaneous 3	10050	Ken Sato	Strategic Principles for Global HCV Elimination: a Comparative Analysis of 12 Countries on Track to Meet Who Targets	Saturday September 19, 2026	15:30-16:06	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 39	Epidemiology and Liver disease 1	10125	Kazuya Okushin	Selective Testing Recommendation Considering Clinical Timelines Improve Opportunities for Hepatitis C Diagnosis	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 39	Epidemiology and Liver disease 1	10000	Ming-Lung Yu	Real-World Effectiveness and Safety of 8-Week Glecaprevir/pibrentasvir for Pwld and HIV Patients from Taiwan Nationwide HCV Registry	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 39	Epidemiology and Liver disease 1	10265	Vinh H Vu	Worse Long-Term Clinical Outcome After Hepatitis C Cure Among People Who Inject Drugs Living with HIV in Vietnam	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 39	Epidemiology and Liver disease 1	10009	Atsushi Ono	Metabolic Dysfunction-Associated Steatotic Liver Disease Increases the Risk of Hepatocellular Carcinoma After Sustained Virologic Response in Chronic Hepatitis C	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 39	Epidemiology and Liver disease 1	10247	Tsubasa Tsutsumi	Low Muscle Mass Across Ckm Stages: Cross-Population Mediation, Mortality, and Multi-Omics Evidence	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 39	Epidemiology and Liver disease 1	10060	K. M. Shakir Ahmed	Prevalence of Hepatitis C Virus Infection Among Prison Inmates: A Cross-Sectional Study at Dhaka Central Jail, Bangladesh	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 40	Epidemiology and Liver disease 2	10361	Joengin Lee	Risk of Mental, Behavioral, and Neurodevelopmental Disorders in Offspring Associated with Maternal Liver Cancer Before Pregnancy	Friday September 18, 2026	17:36-18:06	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 40	Epidemiology and Liver disease 2	10240	Masahito Nakano	Nationwide Trends in Liver Stiffness Measurement in Japan: Real-World Evidence from the National Database of Health Insurance Claims	Friday September 18, 2026	17:36-18:06	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 40	Epidemiology and Liver disease 2	10081	Haruka Taninaka	Non-Cirrhotic Portal Hypertension Caused by a Hepatic Hemangioma-Associated Intrahepatic Arteriportal Shunt Presenting with Ruptured Esophageal Varices Successfully Treated with Transarterial Embolization	Friday September 18, 2026	17:36-18:06	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 40	Epidemiology and Liver disease 2	10228	Hirayuki Enomoto	Etiological Transitions in Patients with Liver Cirrhosis and Hcc-Complicated Cirrhosis: a Single-Center Study from an Institution in a District Area with a High Prevalence of Viral Hepatitis	Friday September 18, 2026	17:36-18:06	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 40	Epidemiology and Liver disease 2	10207	Chi-Yu Lee	Clinical Significance of Durable Response to Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	Friday September 18, 2026	17:36-18:06	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 41	Epidemiology and Liver disease 3	10074	Amjad Khan	Real-World Sorafenib Adverse Events and Quality-Of-Life Trajectories in Advanced Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 41	Epidemiology and Liver disease 3	10180	Maiko Nagaoka	Serum Mac-2 Binding Protein Glycosylation Isomer Is Associated with Physical Frailty in Community-Dwelling Older Adults	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 41	Epidemiology and Liver disease 3	10179	Satoru Kakizaki	Long-Term Outcomes of Sofosbuvir/velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: a Retrospective Multicenter Cohort Study	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 41	Epidemiology and Liver disease 3	10212	Ryoko Asari	Nationwide Integration of Hepatitis B into Antenatal Care for Triple Elimination of Mother-To-Child Transmission of HIV, Syphilis, and Hepatitis B in the Gambia: Early Lessons from Global Fund-Supported Scale-Up	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 41	Epidemiology and Liver disease 3	10283	Kenta Suzuki	Long-Term Outcomes in Patients with Decompensated Cirrhosis Who Achieved SVR: a Multicenter Study	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 42	Epidemiology and Liver disease 4	10133	Hiroki Sugiura	Clinical Utility of a Combined HCV Antibody/antigen Assay: Comparison with a Single Antibody Assay and a Prospective Study	Saturday September 19, 2026	15:30-16:00	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 42	Epidemiology and Liver disease 4	10327	Xiang Zhou	Twenty-Year Trends in Liver Biopsy Practice: from Viral Hepatitis to Steatotic Liver Disease and Autoimmune Liver Diseases	Saturday September 19, 2026	15:30-16:00	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 42	Epidemiology and Liver disease 4	10188	Kazuhiro Kawata	Awareness of Viral Hepatitis Among Junior and Senior High School Students and the Effectiveness of a School-Based Educational Program: a Large-Scale Longitudinal Study	Saturday September 19, 2026	15:30-16:00	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 42	Epidemiology and Liver disease 4	10370	Vikas Sharma	Smartcare-Lc: an AI Driven Digital Ecosystem for Personalized Precision Oncology in Liver Cancer	Saturday September 19, 2026	15:30-16:00	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 42	Epidemiology and Liver disease 4	10301	Takako Inoue	Improving Medical Attendance Confirmation for Hepatitis Testing-Positive Individuals: a Seven-Year Study in Aichi, Japan	Saturday September 19, 2026	15:30-16:00	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 43	Surgical Treatment 1	10159	Tzu Ya Lien	Impact of Initial Surgery on Survival Outcomes in Combined Hepatocellular-Cholangiocellular Carcinoma: a Single-Center Retrospective Analysis	Friday September 18, 2026	18:00-18:30	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 43	Surgical Treatment 1	10038	Takahisa Fujikawa	Multidisciplinary Treatment Combining Systemic Biologic Therapy and Minimally Invasive Hepatectomy for Borderline-Resectable Hepatocellular Carcinoma: an Analysis of 10 Consecutive Cases	Friday September 18, 2026	18:00-18:30	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 43	Surgical Treatment 1	10027	Arjun Maria	Non-Destructive Ebv-Associated Ptd Presenting with Gastrointestinal Bleeding in a Post-Liver Transplant Child: Diagnostic and Therapeutic Challenges	Friday September 18, 2026	18:00-18:30	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 43	Surgical Treatment 1	10321	Masaaki Hidaka	Liver Resection Following Multidisciplinary Treatment for Borderline Resectable Hepatocellular Carcinoma (Br2): a Report of Four Cases	Friday September 18, 2026	18:00-18:30	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 43	Surgical Treatment 1	10181	Aswanth Ks	Impact of Sarcopenia in Early Outcomes of Pediatric Liver Transplantation: a Single-Centre Cohort Study	Friday September 18, 2026	18:00-18:30	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 44	Surgical Treatment 2	10349	Shinji Itoh	Effect of Curative Resection After Atezolizumab Plus Bevacizumab on Outcome in Hepatocellular Carcinoma	Friday September 18, 2026	17:24-18:00	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 44	Surgical Treatment 2	10258	Shinya Hayami	Perioperative Detection of Second Primary Malignancies in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma	Friday September 18, 2026	17:24-18:00	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 44	Surgical Treatment 2	10018	Tomoko Tadokoro	Recurrent Intraoperative Bradycardia During Radiofrequency Ablation for Hepatocellular Carcinoma	Friday September 18, 2026	17:24-18:00	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 44	Surgical Treatment 2	10012	Ekram Hasanin	Novel Trends in Liver Transplantation for MASLD and Ald: Emerging Epidemiology, Allocation& Post-Transplant Challenges	Friday September 18, 2026	17:24-18:00	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 44	Surgical Treatment 2	10221	Yuwa Ando	Hepatic Resection Following Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: a Single-Center Experience and Clinical Implications	Friday September 18, 2026	17:24-18:00	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 44	Surgical Treatment 2	10263	T Oga	A Case of a Rapidly Growing Inflammatory Hepatocellular Adenoma Treated with Robot-Assisted Liver Resection	Friday September 18, 2026	17:24-18:00	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 45	Basic & Translational research 1	10032	Tuan Anh Pham	Cdc80 as a Novel Marker and Therapeutic Target in Liver Fibrosis: a Single-Cell RNA Sequencing Study	Friday September 18, 2026	17:00-17:24	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 45	Basic & Translational research 1	10110	Charupong Saengboonmee	The Impact of Adiposity and Leptin Signaling on Hepatocellular Carcinoma Progression and Patient Prognosis	Friday September 18, 2026	17:00-17:24	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 45	Basic & Translational research 1	10236	Haruna Noguchi	Prime Editing Enables Isogenic Modeling of Pnpla3-I148m-Associated Lipotoxicity in Hepatocytes	Friday September 18, 2026	17:00-17:24	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 45	Basic & Translational research 1	10143	Yan Zhang	Akkermansia-Mediated Nutritional Preconditioning Alleviates Cholestatic Liver Fibrosis via the I3a-Ahr-Nrf2 Axis	Friday September 18, 2026	17:00-17:24	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 46	Basic & Translational research 2	10047	Yuki Kunimune	Quantitative Pcr-Based Measurement of Serum Methylated Sept9 , Hoxa1 , and Sst Achieves Equivalent Diagnostic Performance to Digital PCR for Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 46	Basic & Translational research 2	10284	Yutaka Yasui	Comprehensive Genomic Profiling in Advanced Hepatocellular Carcinoma: Real-World Cohort	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 46	Basic & Translational research 2	10104	Yang Jae Yoo	Machine Learning Based Identification of Exosomal Mir-30a-5p as a Predictive Biomarker for Atezolizumab Plus Bevacizumab Response in Advanced Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 46	Basic & Translational research 2	10138	Tomoyuki Satake	Clinical Outcomes of Cabozantinib During the Ici Era	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 46	Basic & Translational research 2	10264	Naoto Izumi	Long-Term Outcomes After Subsequent Anticancer Treatment for Ruptured Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 47	Miscellaneous and Case Reports 1	10280	Agus Sukanto	From Presumed Hepatocellular Carcinoma to Intrahepatic Cholangiocarcinoma: the Impact of Tissue Diagnosis on Clinical Management and Treatment Outcome	Friday September 18, 2026	17:00-17:30	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 47	Miscellaneous and Case Reports 1	10267	Duong Thuy Phung	Stereotactic Body Radiotherapy (Sbrt) Achieves Lasting Response After Sequential TACE and Multiline Systemic Therapy Failure in Intermediate-Stage Hepatocellular Carcinoma: a Case Report	Friday September 18, 2026	17:00-17:30	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 47	Miscellaneous and Case Reports 1	10279	Tri Hartanto	Occult Satellite Lesions in Low-Afp Hepatocellular Carcinoma: Implications of Afp-Negative Phenotypes in Early-Stage Disease	Friday September 18, 2026	17:00-17:30	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 47	Miscellaneous and Case Reports 1	10313	Yasuhide Motoyoshi	Two Cases of Cytokine Release Syndrome (Crs) During Combination Immunotherapy for Unresectable Hepatocellular Carcinoma	Friday September 18, 2026	17:00-17:30	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 47	Miscellaneous and Case Reports 1	10026	Shiho Miyase	Impact of Liver Steatosis on Hepatocarcinogenesis in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Analog Therapy	Friday September 18, 2026	17:00-17:30	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 48	Miscellaneous and Case Reports 2	10237	Song Huy Nguyen Dinh	Hepatocellular Carcinoma (HCC): Challenges in Screening, Diagnosis, and Management in Vietnam	Friday September 18, 2026	17:30-18:00	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 48	Miscellaneous and Case Reports 2	10257	Chang-Chieng Soon	Immune-Mediated Clopidogrel-Induced Drug-Induced Liver Injury Confirmed by Drug-Specific Lymphocyte Transformation Test: a Case Report and Literature Review	Friday September 18, 2026	17:30-18:00	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 48	Miscellaneous and Case Reports 2	10375	Ngoc Minh Nguyen	Hepatitis B Prevention Knowledge and Attitudes Among Medical Students in Low- and Middle-Income Countries: a Systematic Review	Friday September 18, 2026	17:30-18:00	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 48	Miscellaneous and Case Reports 2	10157	Balaussa Absamat	Self-Reported Hepatitis B Vaccination Status and Knowledge, Attitudes, and Practices Towards Hepatitis B Among Medical Students in Kazakhstan: a Cross-Sectional Study	Friday September 18, 2026	17:30-18:00	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 48	Miscellaneous and Case Reports 2	10061	Akinobu Tawada	Overcoming International Disparities in Accessibility for Anticancer Drugs: an Ecological Study Using Country-Level Data	Friday September 18, 2026	17:30-18:00	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.

Style	Group	Session Name	No	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Poster	Group 49	Miscellaneous and Case Reports 3	10248	Tanusree Saha Mumu	Hepatic Amyloidosis Presenting as Cholestatic Liver Disease with Portal Hypertension: a Case Report	Saturday September 19, 2026	15:30-16:00	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 49	Miscellaneous and Case Reports 3	10062	Yuri Sakamoto	A Case of Sclerosing Cholangitis That Was Difficult to Differentiate from Intrahepatic Cholangiocarcinoma	Saturday September 19, 2026	15:30-16:00	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 49	Miscellaneous and Case Reports 3	10282	Kazuya Minamoto	A Case of Pet-Negative Intrahepatic Cholangiocarcinoma That Was Difficult to Diagnose	Saturday September 19, 2026	15:30-16:00	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 49	Miscellaneous and Case Reports 3	10082	Shohei Miyabe	A Case of Intrahepatic Cholangiocarcinoma Achieving Remarkable Tumor Regression via Heavy-Ion Radiotherapy Followed by Immunotherapy	Saturday September 19, 2026	15:30-16:00	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 49	Miscellaneous and Case Reports 3	10148	Taro Shibuki	Sex-Based Outcomes of First-Line Systemic Therapy in Advanced Intrahepatic Cholangiocarcinoma	Saturday September 19, 2026	15:30-16:00	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 50	Miscellaneous and Case Reports 4	10033	Babylyn Oab	Fever Without Focus: an Atypical Presentation of Hypervirulent Klebsiella Pneumoniae Liver Abscess in Newly Diagnosed Diabetes Mellitus	Saturday September 19, 2026	16:00-16:30	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 50	Miscellaneous and Case Reports 4	10191	Tatsuo Kanda	Acute-On-Chronic Liver Failure Following Pneumonia in an Elderly Woman with Metabolic Dysfunction-Associated Steatotic Liver Cirrhosis	Saturday September 19, 2026	16:00-16:30	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 50	Miscellaneous and Case Reports 4	10122	Takeshi Chida	HBV Genomic Sequences Detected by Comprehensive Genomic Profiling Provided a Clue to the Diagnosis of Metastatic Hepatocellular Carcinoma	Saturday September 19, 2026	16:00-16:30	16:12	16:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 50	Miscellaneous and Case Reports 4	10337	Tatsuo Kanda	Pemafibrate Effectively Prevented Liver Dysfunction in Young Female with Anorexia Nervosa	Saturday September 19, 2026	16:00-16:30	16:18	16:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Poster	Group 50	Miscellaneous and Case Reports 4	10356	Hirotoشي Ebinuma	A Case of HCC Presenting with Gastric Ulcers by VEGF Inhibition	Saturday September 19, 2026	16:00-16:30	16:24	16:30	Presentation: 4min. QA Time: 2min. Total: 6min.